Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  NATIONAL STOCK EXCHANGE OF INDIA  >  Lupin    LUPIN   INE326A01037

LUPIN (LUPIN)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets
OFFRE ETE Zonebourse : Jusqu'à 6 mois offerts sur tous les portefeuilles

Lupin Limited : Lupin Looking for Acquisitions of up to $500 Million in US

share with twitter share with LinkedIn share with facebook
share via e-mail
0
08/01/2012 | 12:39pm CEST

--Looking for buys in skin care, eye care, respiratory and women's health products

--Trying to expand pipeline of low-competition generic drugs for US market

(Adds executive's comments in 7th, 9th, 12th and 13th paragraphs, background and context elsewhere)

By Rumman Ahmed

BANGALORE--Lupin Ltd. (500257.BY) is looking to aggressively grow its business in the U.S. and is scouting for acquisitions of pharmaceutical brands and manufacturers, and seeking regulatory approval to sell a wider range of niche generic drugs.

The U.S. is Lupin's primary growth market, accounting for 35% of its sales.

The India drug maker is benefiting from a wave of patent expiries for popular drugs in the U.S. But to keep the business momentum going once the "patent cliff" wave wanes, Lupin is looking to acquire branded products that are much bigger that its previous purchases.

"We've looked at small-sized acquisition opportunities as well as opportunities in the $400 million-$500 million price range," group president Vineeta Gupta recently told Dow Jones Newswires.

Unlike most of its local rivals, Lupin's business model for the world's largest pharmaceuticals market is not limited to selling drug copies: It also sells branded products like antibiotic Suprax and anti-cholesterol drug Antara. While the branded products contribute about 25% of Lupin's U.S. revenue, they make up a larger share of its profit.

Lupin is looking for acquisitions to revive the momentum in the branded-products business at a time when existing brands are likely to come up against generic competition.

The company would prefer acquisitions in the areas of skin care, eye care, respiratory and women's health products, which are more in line with the company's commercial infrastructure in the U.S., Ms. Gupta said.

The company's 160-person sales force in the U.S. is focused on selling branded products to the pediatric and primary-care market segments.

Ms. Gupta, who also heads Lupin's U.S. unit, said Lupin had mulled acquiring eye-care company ISTA Pharmaceuticals Inc., but found it wasn't a "good fit."

Eye-products maker Bausch & Lomb Inc. purchased ISTA for about $500 million in cash in a deal that closed in June.

Lupin's previous acquisitions in the U.S. were much smaller in comparison. In 2009 it paid $38.61 million to bankrupt Oscient Pharmaceuticals Corp. for Antara, and acquired AllerNaze nasal spray from U.S.-based Collegium Pharmaceutical Inc. for an undisclosed amount.

As for its generic drugs business, Lupin is trying to move its pipeline to products that are exclusive and face less competition, Ms. Gupta said.

Lupin has already applied to sell generic versions of about 31 oral contraceptive products and some eye treatments. It has also filed the first generic drug application with the U.S. regulator for a skin care product in the January-March period, she added.

Benefits from selling these drugs, which have relatively high entry barriers and offer higher-than-average margins, are expected to kick in from the fiscal year starting next April.

Write to Rumman Ahmed at [email protected]

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on LUPIN
06/15LUPIN : launches generic Tobramycin Inhalation Solution USP in the US
AQ
06/06LUPIN : launches generic Methylergonovine Maleate Tabs USP in the US
AQ
06/06LUPIN : receives FDA approval for generic Nystatin and Triamcinolone Acetonide C..
AQ
06/05LUPIN : Usfda nod to lupin's fungal infection cream
AQ
06/05LUPIN : Launches generic drug in us markets
AQ
05/17LUPIN : Reports from Lupin, Ltd. Advance Knowledge in Central Nervous System Age..
AQ
05/16LUPIN : POSTS Q4 NET LOSS OF Rs783 CRORE ON ONE-TIME WRITE-OFF
AQ
05/15LUPIN LTD'S Q4FY18 CONSOLIDATED ADJU : Beats Estimates
AQ
05/15LUPIN : Annual results
CO
05/14LUPIN : Nagpur plant completes successful USFDA inspection
AQ
More news
Financials ( INR)
Sales 2019 169 B
EBIT 2019 22 525 M
Net income 2019 15 879 M
Debt 2019 37 808 M
Yield 2019 0,73%
P/E ratio 2019 25,33
P/E ratio 2020 20,67
EV / Sales 2019 2,63x
EV / Sales 2020 2,32x
Capitalization 406 B
Chart LUPIN
Duration : Period :
Lupin Technical Analysis Chart | LUPIN | INE326A01037 | 4-Traders
Technical analysis trends LUPIN
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 42
Average target price 834  INR
Spread / Average Target -7,4%
EPS Revisions
Managers
NameTitle
Nilesh Deshbandhu Gupta Managing Director & Executive Director
Vinita D. Gupta Chief Executive Officer & Executive Director
Manju Deshbandhu Gupta Chairman
Ramesh Swaminathan Chief Financial Officer & Executive Director
Alok Ghosh President-Technical Operations
Sector and Competitors
1st jan.Capitalization (M$)
LUPIN1.18%5 955
JOHNSON & JOHNSON-12.27%328 751
PFIZER0.00%211 871
NOVARTIS-10.17%188 057
ROCHE HOLDING LTD.-12.19%183 625
MERCK AND COMPANY8.90%164 189